Pipeline and Clinical Trials
Corcept Sponsored Trials
Cushing’s Syndrome
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Endogenous Cushing syndrome (GRACE)
Compound
Relacorilant
Currently in Phase Three
Target Indication (Study Name)
Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)
Compound
Relacorilant
Currently in Phase Three
Target Indication (Study Name)
Extension study to evaluate long term safety
Compound
Relacorilant
Phase Two
Oncology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Platinum-resistant ovarian cancer (ROSELLA)
Compound
Relacorilant + Abraxane (nab-paclitaxel)
Currently in Phase Three
Target Indication (Study Name)
Adrenal cancer with cortisol excess
Compound
Relacorilant + Keytruda (pembrolizumab)
Phase One
Metabolic Diseases
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
Recent antipsychotic-induced weight gain (GRATITUDE)
Compound
Miricorilant
Phase Two
Target Indication (Study Name)
Long-standing antipsychotic-induced weight gain (GRATITUDE II)
Compound
Miricorilant
Phase Two
Target Indication (Study Name)
NASH
Compound
Miricorilant
Phase One
Neurology
Target Indication (Study Name)
Compound
Phase I
Phase II
Phase III
Target Indication (Study Name)
ALS (DAZALS)
Compound
Dazucorilant
Phase Two
Investigator Sponsored Trials
Oncology
Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Triple-negative breast cancer
Compound
Mifepristone + Abraxane (nab-paclitaxel)1
Phase Two
Target Indication
Prostate cancer
Compound
Relacorilant + Xtandi (enzalutamide)1
Phase Two
Addiction
Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alcohol use disorder
Compound
Miricorilant + Behavioral Therapy2
Phase Two
Psychiatry
Target Indication
Compound
Phase I
Phase II
Phase III
Target Indication
Alzheimer’s disease
Compound
CORT1082973
Phase Two
Target Indication
PTSD
Compound
CORT1082974
Phase Two
Target Indication
Major depression
Compound
Mifepristone5
Phase Two
Additional Areas of Research
Alzheimer’s disease
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Anxiety
Diabetes
Hypertension
Neurodegenerative diseases
Nonsmall cell lung cancer
Obesity
Obesity
GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis.
1University of Chicago.
2Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism.
3John Hopkins University.
4VA Office of Research and Development.
5Amsterdam UMC.